This article was originally published in The Gray Sheet
Executive SummaryNames Clive Patrickson president and CEO, replacing Tom Burns, who is stepping down to take an early "semi-retirement." Patrickson established a Laerdal subsidiary in Australia, where he has spent the past five years. Burns, who has been with the company for nine years, will remain with Laerdal in a consulting capacity
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.